Saniona announced the further expansion of its executive team with the appointments of Denelle Waynick as Chief Legal Officer and Kyle Haraldsen as Chief Technical Operations Officer. The positions will be based in the U.S. and will support Saniona's advancement of clinical trials for Tesomet and SAN 711 as well as the company's growing U.S. presence. Denelle Waynick, Chief Legal Officer, has nearly 30 years of experience advising domestic and international companies in the healthcare and life sciences industries. Most recently, Waynick served as Chief Legal Officer and Corporate Secretary at MyoKardia, where she provided strategic and practical counsel to C-suite executives in legal matters, as well as issues impacted by the regulatory and policy environment. Waynick has also worked as in-house corporate counsel at UCB, Actavis and Schering-Plough, and in corporate law as an Associate and Partner at national and regional law firms. In addition to expertise in corporate, policy, governance and litigation matters, she has served as counsel on a range of global business transactions, including mergers, acquisitions and divestments. Kyle Haraldsen, Chief Technical Operations Officer, has nearly 20 years of technical operations and manufacturing experience in the biopharmaceutical industry, including in support of U.S. and E.U. product approvals. Most recently, he served as the Vice President of Technical Operations and Project Management at AMAG Pharmaceuticals, where he led the process and analytical development, manufacturing, supply chain and project management functions. During his time at AMAG, Haraldsen oversaw multiple product launches, line extensions and the integration of two development stage assets. Prior to his time at AMAG, he was the Senior Director of Manufacturing at Radius Health, where he was responsible for the developmental, operational, and budgetary oversight of CMC programs and clinical trial material in support of global Phase 3 and multinational Phase 2 clinical trials. Haraldsen also worked for contract manufacturers Avecia Biotechnology and Johnson Matthey Pharma Services.